Kerri Fitzgerald

DocwireNews

Acalabrutinib in combination with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) was well tolerated and may improve efficacy for patients with untreated diffuse large B-cell lymphoma (DLBCL), according to a study presented at the 2020 ASH Annual Meeting.The study included treatment-na&iuml;ve patients with histologically confirmed DLBCL who received six cycles of R&#8208;CHOP plus acalabrutinib in cycles two through six. In a continuation phase, patients received acalabrutinib only for two 28-day cycles after R-CHOP.The primary objective of the phase Ib study was to establish a recommended phase II dose of acalabrutinib in combination with R&#8208;CHOP (modified classical 6+6 design). Phase II assessed the overall response rate (ORR) of the combination and safety outcomes. Between May 2017 and January 2020, 38 patients (median age, 64 years; range, 24-80 years; 39% were &gt;65 years) were enrolled. Most (74%) had stage III/IV disease, and 26% had high International Prognostic Index scores. Seven patients were ultimately ineligible for the study.Researchers observed no dose-limiting toxicities, and the maximum tolerated dose of acalabrutinib was not reached. The recommended phase II dose was acalabrutinib 100 mg twice daily.The most common&nbsp;grade &ge;3 adverse events (AEs) were neutropenia (26%), febrile neutropenia (13%), and diarrhea (11%), and the most common serious AE was febrile neutropenia (13%). Age did not impact patients&rsquo; ability to receive full doses of R-CHOP plus acalabrutinib. One patient in the first cohort who was receiving acalabrutinib 100 mg progressed on therapy and ultimately died.Among 24 eligible patients who received the acalabrutinib 100 mg twice daily in either the dose escalation or expansion phase, 22 patients have responded to treatment. Four patients withdrew early from treatment and were included in the efficacy analysis.The ORR was 95%, with 82% of patients achieving a metabolic complete response (CR), including three partial responses and one with stable disease. One patient with&nbsp;MYC/BCL2/BCL6 rearrangements and one with&nbsp;MYC/BCL2&nbsp;rearrangement achieved a metabolic CR, neither of whom have progressed on treatment.Twelve-month progression-free and overall survival were both 100% in patients who received the recommended phase II dose of acalabrutinib. R-CHOP did not affect the pharmacokinetics of acalabrutinib, according to the authors.This treatment combination should be explored in randomized trials, the researchers noted.ReferenceDavies A, Caddy J, Mercer K, et al. Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) As First Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL): The Accept Phase Ib/II Single Arm Study. Abstract 1185. Presented at the 62nd American Society of Hematology Annual Meeting &amp; Exposition, December 2-11, 2020.

Jordana Jampel

Positive Preliminary Results From Phase 1 Trial of Dopaminergic Neuron Graft for Parkinson’s Disease

Dementia

Bradley Warady, MD

Joel M. Topf, MD, FACP

2025 Hume Award Winner Is Dedicated to Children’s Care

NKF Spring Clinical Meetings 2025

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Latest News

Acalabrutinib Plus R-CHOP for Untreated DLBCL

ASH Annual Meeting 2020

Acalabrutinib in combination with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) was well tolerated and may improve efficacy for patients with ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe